secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARVINAS, INC. (ARVN)
CIK:        0001655759
Form:       8-K
Filed at:   2026-05-12T11:15:37+00:00
Accession:  0001628280-26-033875
Event type: earnings
Sentiment:  positive
Materiality: 1.00
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arvinas reports Q1 2026; FDA approves first PROTAC VEPPANU; licenses to Rigel
-----------------------------------------------------------------------------

- FDA approved VEPPANU (vepdegestrant) for ESR1m, ER+/HER2- advanced breast cancer — first PROTAC therapy approved.
- Entered license agreement with Rigel Pharmaceuticals for exclusive global rights to VEPPANU; closing subject to HSR approval.
- Cash and equivalents $614.9M at Mar 31, 2026 (Dec 31, 2025: $685.4M); cash runway into 2H 2028.
- Randy Teel appointed President, CEO, and Director; Briggs Morrison elected Chair of the Board.
- ARV-102 Phase 1: >50% LRRK2 degradation in CSF; ARV-806 KRAS G12D dose escalation complete; ARV-027 Phase 1 initiated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1655759/000162828026033875/0001628280-26-033875-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1655759/000162828026033875/arvn-20260512.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-033875

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer